![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Deep Sequencing of HCV NS5A From a 3-Day Study of GS-5816 Monotherapy Confirms the Potency
of GS-5816 Against Pre-Existing Genotype 1-3 NS5A Resistance-Associated Variants
|
|
|
Reported by Jules Levin
Presented at The Liver Meeting® 2013: 64th Annual Meeting of the American Association for the Study of Liver Diseases, November 1-5, 2013, Washington, DC
Brian Doehle,1 Hadas Dvory-Sobol,1 Christy Hebner,1 Viktoria Gontcharova,1 Krishna Chodavarapu,1 Wen Ouyang,1 Maribel Rodriguez-Torres,2 Eric Lawitz,3 Chris Yang,1 John McNally,1 John Link,1 Hongmei Mo1
1Gilead Sciences, Inc., Foster City, CA; 2Fundacion de Investigacion de Diego, San Juan, Puerto Rico; 3Texas Liver Institute, University of Texas Health Sciences Center, San Antonio, TX
![AASLD1.gif](../images/110313/110313-4/AASLD1.gif)
![AASLD2.gif](../images/110313/110313-4/AASLD2.gif)
![AASLD3.gif](../images/110313/110313-4/AASLD3.gif)
![AASLD4.gif](../images/110313/110313-4/AASLD4.gif)
![AASLD5.gif](../images/110313/110313-4/AASLD5.gif)
![AASLD6.gif](../images/110313/110313-4/AASLD6.gif)
![AASLD7.gif](../images/110313/110313-4/AASLD7.gif)
![AASLD8.gif](../images/110313/110313-4/AASLD8.gif)
![AASLD9.gif](../images/110313/110313-4/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|